Cargando…
The TAM family as a therapeutic target in combination with radiation therapy
Radiation therapy is primarily a modality to kill cancer cells in the treatment field. It is becoming increasingly clear that radiation therapy can also be used to direct immune responses that have the potential to clear residual local or distant disease outside the treatment field. We believe that...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093058/ https://www.ncbi.nlm.nih.gov/pubmed/32211517 http://dx.doi.org/10.1042/ETLS20170066 |
_version_ | 1783510224798220288 |
---|---|
author | Tormoen, Garth W. Crittenden, Marka R. Gough, Michael J. |
author_facet | Tormoen, Garth W. Crittenden, Marka R. Gough, Michael J. |
author_sort | Tormoen, Garth W. |
collection | PubMed |
description | Radiation therapy is primarily a modality to kill cancer cells in the treatment field. It is becoming increasingly clear that radiation therapy can also be used to direct immune responses that have the potential to clear residual local or distant disease outside the treatment field. We believe that cancer cell death is the critical link between these processes. Understanding the handling of dying cancer cells by immune cells in the tumor environment is crucial to facilitate immune responses following radiation therapy. We review the role of the TAM (Tyro3 Axl Mertk) group of receptor tyrosine kinases and their role following radiation-induced cancer cell death in the tumor environment. |
format | Online Article Text |
id | pubmed-7093058 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Portland Press Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70930582020-03-24 The TAM family as a therapeutic target in combination with radiation therapy Tormoen, Garth W. Crittenden, Marka R. Gough, Michael J. Emerg Top Life Sci Review Articles Radiation therapy is primarily a modality to kill cancer cells in the treatment field. It is becoming increasingly clear that radiation therapy can also be used to direct immune responses that have the potential to clear residual local or distant disease outside the treatment field. We believe that cancer cell death is the critical link between these processes. Understanding the handling of dying cancer cells by immune cells in the tumor environment is crucial to facilitate immune responses following radiation therapy. We review the role of the TAM (Tyro3 Axl Mertk) group of receptor tyrosine kinases and their role following radiation-induced cancer cell death in the tumor environment. Portland Press Ltd. 2017-12-15 2017-12-12 /pmc/articles/PMC7093058/ /pubmed/32211517 http://dx.doi.org/10.1042/ETLS20170066 Text en © 2017 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and the Royal Society of Biology and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Review Articles Tormoen, Garth W. Crittenden, Marka R. Gough, Michael J. The TAM family as a therapeutic target in combination with radiation therapy |
title | The TAM family as a therapeutic target in combination with radiation therapy |
title_full | The TAM family as a therapeutic target in combination with radiation therapy |
title_fullStr | The TAM family as a therapeutic target in combination with radiation therapy |
title_full_unstemmed | The TAM family as a therapeutic target in combination with radiation therapy |
title_short | The TAM family as a therapeutic target in combination with radiation therapy |
title_sort | tam family as a therapeutic target in combination with radiation therapy |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093058/ https://www.ncbi.nlm.nih.gov/pubmed/32211517 http://dx.doi.org/10.1042/ETLS20170066 |
work_keys_str_mv | AT tormoengarthw thetamfamilyasatherapeutictargetincombinationwithradiationtherapy AT crittendenmarkar thetamfamilyasatherapeutictargetincombinationwithradiationtherapy AT goughmichaelj thetamfamilyasatherapeutictargetincombinationwithradiationtherapy AT tormoengarthw tamfamilyasatherapeutictargetincombinationwithradiationtherapy AT crittendenmarkar tamfamilyasatherapeutictargetincombinationwithradiationtherapy AT goughmichaelj tamfamilyasatherapeutictargetincombinationwithradiationtherapy |